Literature DB >> 21888967

The encapsulation of β-lapachone in 2-hydroxypropyl-β-cyclodextrin inclusion complex into liposomes: a physicochemical evaluation and molecular modeling approach.

Isabella M F Cavalcanti1, Elisângela A M Mendonça, Mariane C B Lira, Sara B Honrato, Celso A Camara, Rosa V S Amorim, Josué Mendes Filho, Marcelo M Rabello, Marcelo Z Hernandes, Alejandro P Ayala, Nereide S Santos-Magalhães.   

Abstract

The aim of this study was to encapsulate lapachone (β-lap) or inclusion complex (β-lap:HPβ-CD) in liposomes and to evaluate their physicochemical characteristics. In addition, the investigation of the main aspects of the interaction between β-lap and 2-hydroxypropyl-β-cyclodextrin (HPβ-CD), using both experimental and molecular modeling approaches was discussed. Furthermore, the in vitro drug release kinetics was evaluated. First, a phase solubility study of β-lap in HPβ-CD was performed and the β-lap:HPβ-CD was prepared by the freeze-drying technique. A 302-fold increase of solubility was achieved for β-lap in HPβ-CD solution with a constant of association K(1:1) of 961 M(-1) and a complexation efficiency of β-lap of 0.1538. (1)H NMR, TG, DSC, IR, Raman and SEM indicated a change in the molecular environment of β-lap in the inclusion complex. Molecular modeling confirms these results suggesting that β-lap was included in the cavity of HPβ-CD, with an intermolecular interaction energy of -23.67 kJ mol(-1). β-lap:HPβ-CD and β-lap-loaded liposomes presented encapsulation efficiencies of 93% and 97%, respectively. The kinetic rate constants of 183.95±1.82 μg/h and 216.25±2.34 μg/h were calculated for β-lap and β-lap:HPβ-CD-loaded liposomes, respectively. In conclusion, molecular modeling elucidates the formation of the inclusion complex, stabilized through hydrogen bonds, and the encapsulation of β-lap and β-lap:HPβ-CD into liposomes could provide an alternative means leading eventually to its use in cancer research.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21888967     DOI: 10.1016/j.ejps.2011.08.011

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   5.112


  8 in total

1.  Enhanced antiproliferative activity of the new anticancer candidate LPSF/AC04 in cyclodextrin inclusion complexes encapsulated into liposomes.

Authors:  Elisângela A M Mendonça; Mariane C B Lira; Marcelo M Rabello; Isabella M F Cavalcanti; Suely L Galdino; Ivan R Pitta; Maria do Carmo A Lima; Maira G R Pitta; Marcelo Z Hernandes; Nereide S Santos-Magalhães
Journal:  AAPS PharmSciTech       Date:  2012-10-02       Impact factor: 3.246

2.  Inclusion Complex between Local Anesthetic/2-hydroxypropyl-β-cyclodextrin in Stealth Liposome.

Authors:  Gredson Keiff Souza; André Gallo; Luiza Hauser Novicki; Heitor Rodrigues Neto; Eneida de Paula; Anita Jocelyne Marsaioli; Luis Fernando Cabeça
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

3.  Encapsulation of nor-β-lapachone into poly(d,l)-lactide-co-glycolide (PLGA) microcapsules: full characterization, computational details and cytotoxic activity against human cancer cell lines.

Authors:  Marcília P Costa; Anderson C S Feitosa; Fátima C E Oliveira; Bruno C Cavalcanti; Gleiston G Dias; Ewerton W S Caetano; Francisco A M Sales; Valder N Freire; Stefano Di Fiore; Rainer Fischer; Luiz O Ladeira; Eufrânio N da Silva Júnior; Claudia Pessoa
Journal:  Medchemcomm       Date:  2017-09-07       Impact factor: 3.597

Review 4.  Enhancing Oral Absorption of β-Lapachone: Progress Till Date.

Authors:  Marival Bermejo; Victor Mangas-Sanjuan; Isabel Gonzalez-Alvarez; Marta Gonzalez-Alvarez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.569

5.  Enzymatic synthesis and in vitro evaluation of folate-functionalized liposomes.

Authors:  Bohong Guo; Danqiao Xu; Xiaohong Liu; Jun Yi
Journal:  Drug Des Devel Ther       Date:  2017-06-20       Impact factor: 4.162

6.  Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed, in vitro, on Leishmania (L) amazonensis Amastigotes-Hosted in Mouse CBA Macrophages.

Authors:  Antonio Luis de Oliveira Almeida Petersen; Thiers A Campos; Diana Angélica Dos Santos Dantas; Juliana de Souza Rebouças; Juliana Cruz da Silva; Juliana P B de Menezes; Fábio R Formiga; Janaina V de Melo; Giovanna Machado; Patrícia S T Veras
Journal:  Front Cell Infect Microbiol       Date:  2018-08-30       Impact factor: 5.293

7.  Nanoliposome-Encapsulated Brinzolamide-hydropropyl-β-cyclodextrin Inclusion Complex: A Potential Therapeutic Ocular Drug-Delivery System.

Authors:  Fazhan Wang; Xingting Bao; Aiping Fang; Huili Li; Yang Zhou; Yongmei Liu; Chunling Jiang; Jinhui Wu; Xiangrong Song
Journal:  Front Pharmacol       Date:  2018-02-13       Impact factor: 5.810

8.  Synergistic Effect of Acetazolamide-(2-hydroxy)propyl β-Cyclodextrin in Timolol Liposomes for Decreasing and Prolonging Intraocular Pressure Levels.

Authors:  Carmen M Arroyo-García; Daniela Quinteros; Santiago D Palma; Cesáreo J Jiménez de Los Santos; José R Moyano; Antonio M Rabasco; María Luisa González-Rodríguez
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.